

S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. **Erythropoietin-Receptor agonists:**
 - 1.1 **Erythropoiesis-Stimulating Agents (ESAs)** including e.g. **darbepoietin (dEPO); erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP)**, e.g. **CNTO 530** and **peginesatide; GATA inhibitors**, e.g. **K-11706; methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor- β (TGF-13) inhibitors**, e.g. **sotatercept, luspatercept**;
 - 1.2 **Non-erythropoietic EPO-Receptor agonists**, e.g. **ARA-290; asialo EPO; carbamylated EPO**;
2. **Hypoxia-inducible factor (HIF) stabilizers**, e.g. **cobalt, molidustat and roxadustat (FG-4592)**; and **HIF activators**, e.g. **argon and xenon**;
3. **Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)** and their releasing factors, e.g. **buserelin, gonadorelin and leuprorelin**, in males;
4. **Corticotrophins** and their releasing factors, e.g. **corticoirelin**;
5. **Growth Hormone (GH)** and its releasing factors including: **Growth Hormone Releasing Hormone (GHRH)** and its **analogues**, e.g. **CJC-1295, sermorelin and tesamorelin**; **Growth Hormone Secretagogues (GHS)**, e.g. **ghrelin** and **ghrelin mimetics**, e.g. **anamorelin** and **ipamorelin**; **GH-Releasing Peptides (GHRPs)**, e.g. **alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2)**.

Additional prohibited growth factors:

Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its **analogues**; **Mechano Growth Factors (MGFs)**; **Platelet-Derived Growth Factor (PDGF)**; **Vascular-Endothelial Growth Factor (VEGF)** and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.